Bart van de Warrenburg
Associate professor, neurologist, principal investigator
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Background Neuropathological examinations in spinocerebellar ataxia type 3 (SCA3) have demonstrated peripheral and autonomic nervous system degeneration, but the impact of associated symptoms on genetically affected individuals at different disease stages remains understudied. Objective To investigate the clinical burden of peripheral and autonomic nervous system involvement in SCA3 mutation carriers across the disease spectrum. Methods Forty SCA3 mutation carriers, including ten pre-ataxic individuals, completed questionnaires about muscle cramps, neuropathic pain, autonomic symptoms, activities of daily living, and quality of life, and underwent a standardized clinical examination of ataxia and neuropathy severity. Data were compared with 16 healthy controls. Results All but one of the ataxic and 60% of pre-ataxic individuals experienced muscle cramps at least weekly. Neuropathic pain was reported by 20% of pre-ataxic and 16.7% of ataxic mutation carriers, while the average number of autonomic symptoms in both groups was 2 and 4.7, respectively. Neuropathy severity scores were significantly higher in pre-ataxic and ataxic individuals than in healthy controls and associated with (i) worse self-reported functional status and (ii) clinician-reported ataxia severity. The number of autonomic symptoms was associated with patient-reported impairments in daily life and quality of life. Conclusion Clinical features of peripheral and autonomic nervous system degeneration are very common in SCA3, may already be observed in pre-ataxic individuals, and independently contribute to patient-reported disease burden and clinician-rated overall ataxia severity.
Year:
2026
Objective Spinocerebellar ataxia type 3 (SCA3) is a rare, inherited neurodegenerative disease. Here, we profile the spatial spread of atrophy across the whole brain, determine whether brain degeneration preferentially maps onto specific functional networks, and investigate the relationship between cerebellar and cerebral anatomical changes. Methods Whole-brain grey and white matter (GM and WM) voxel-based morphometry was performed on 408 individuals with SCA3 (82 pre-ataxic) and 293 controls. The SCA3 cohort was stratified by ataxia severity to investigate disease progression, with cerebellar GM atrophy mapped onto a task-based functional atlas. Volume was correlated with disease duration and intensity. Cerebrocerebellar volumetric covariance was assessed to determine whether atrophy was coupled between infra- and supratentorial regions. Results The pattern of atrophy is spatially consistent but progressive in magnitude across the disease course. The greatest atrophy was found in the pons, cerebellar WM, and cerebellar peduncles; correlations with disease severity and duration were also strongest in these regions. Cerebellar GM atrophy was greatest in functional regions associated with motor execution and planning, attention, and emotional processing. Sparse cerebral cortical atrophy appears only in the most severe disease subgroup, while striatal atrophy begins in the earliest stages. Reduced cerebrocerebellar structural covariance is observed in SCA3 participants versus controls. Interpretation While cerebellar and brainstem atrophy become more severe, the pattern of atrophy remains largely consistent as SCA3 progresses. Cerebellar GM degeneration occurs in regions associated with motor, cognitive, and affective control, in line with clinical presentation. Cerebellar atrophy is not directly mirrored by cerebral changes.
Year:
2025
Background Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominantly inherited adult-onset disease. We aimed to describe longitudinal changes in clinical and biological findings and to identify predictors for clinical progression. Methods We used data from participants enrolled in the ESMI cohort collected between Nov 09, 2016 and July 18, 2023. The data freeze included data from 14 sites in five European countries and the United States. We assessed ataxia with the Scale for the Assessment and Rating of Ataxia (SARA). We measured disease-specific mutant ataxin-3 protein (ATXN3) and neurofilament light chain (NfL) in plasma and performed MRIs. Data were analysed by regression modelling on a timescale defined by onset. The onset of abnormality of a marker was defined as the time at which its value, as determined by modelling, exceeded the mean ±2 SD of healthy controls. To study responsiveness of markers, we determined the sensitivity to change ratios (SCSs). Results Data from 291 SCA3 mutation carriers before and after clinical onset and 121 healthy controls were included. NfL levels became abnormal more than 20 years (-21.5 years [95% CI n.d. –9.5]) before onset. The earliest MRI abnormality was volume loss of medulla oblongata (-4.7 years [95% CI n.d. – 3.3]). The responsiveness of markers depended on the disease stage. Across all stages, pons volume had the highest responsiveness with an SCS of 1.35 [95% CI 1.11 – 1.78] exceeding that of SARA (0.99 [95% CI 0.88 – 1.11]). Lower age (p=0.0459) and lower medulla oblongata volume (p<0.0001) were predictors of SARA progression. Conclusion Our study provides quantitative information on the progression of biological markers in SCA3 mutation carriers before and after onset of ataxia, and allowed the identification of predictors for clinical progression. Our data could prove useful for the design of future clinical trials.
Year:
2025
Background Although genetic interventions are on the horizon for some polyglutamine expansion diseases, such as subtypes of spinocerebellar ataxia (SCA) and Huntington’s disease (HD), the patients’ preferences regarding these new therapies are unclear. This study aims to get insight into what extent different characteristics of genetic interventions affect the preferences of patients with SCA and HD with regard to these interventions. Methods Manifest and premanifest patients with SCA or HD were recruited online by platforms of patient associations. The respondents conducted a questionnaire that included a discrete choice experiment (DCE). The experimental design included 24 choice sets, but these were divided into three blocks of eight to reduce the number of tasks per respondent. Each choice set included two alternative treatments and consisted of four attributes (mode and frequency of administration, chance of a beneficial effect, risks, and follow-up), each with three or four different levels. The forced choice-elicitation format was used. Data were analyzed by using a multinominal logistic regression model. Results Responses of 216 participants were collected. The mode and frequency of administration of a genetic intervention, as well as the chance of a beneficial effect both influence the choice for a genetic intervention. Respondents less prefer repeated lumbar punctures compared to a single operation. As expected, a higher beneficial effect of treatment was preferred. Risks and follow-up did not influence the choice for a genetic intervention. Conclusions The results can be used for the design and implementation of future genetic interventional trials as well as of patient-centered care pathways for rare movement disorders such as SCA and HD.
Year:
2024
Background and Objectives With targeted treatment trials on the horizon, identification of sensitive and valid outcome measures becomes a priority for the >100 spastic ataxias. Digital-motor measures, assessed by wearable sensors, are prime outcome candidates for SPG7 and other spastic ataxias. We here aimed to identify candidate digital-motor outcomes for SPG7 – as one of the most common spastic ataxias – that: (i) reflect patient-relevant health aspects, even in mild, trial-relevant disease stages; (ii) are suitable for a multi-center setting; and (iii) assess mobility also during uninstructed walking simulating real-life. Methods Cross-sectional multi-center study (7 centers, 6 countries). Unaided walking was assessed in 65 patients with SPG7 and 50 unrelated healthy controls using 3 wearable sensors (Opal APDM). Digital gait measures were correlated to measures of disease severity (SARA, SPRS; including mobility-relevant subscores SPRS 1315291292025 , SARA PG ) and activities of daily living (FARS-ADL). The task set included lab-based defined gait tasks, complemented by uninstructed ‘supervised free walking’. Results Among 30 hypothesis-based gait measures, 18 demonstrated at least moderate effect size (Cliff’s δ>0.5) in discriminating SPG7 patients from controls, and 17 even in mild disease stages (SPRS mobility ≤9). Spatiotemporal variability measures such as the spatial variability composite measure SPcmp (ρ=0.67, p=<0.0001), Stride Time CV (ρ=0.67, p=<0.0001) and Swing CV (ρ=0.64, p=<0.0001) showed the highest correlations with clinician-reported mobility scores (SPRS mobility ), and overall disease severity (SPRS, SARA). Overall, top-ranked measures also correlated with patient-relevant functional deficits in everyday life activities (FARS-ADL). In mild disease stages (SPRS mobility ≤9, n=41), Swing CV (ρ=0.53, p=<0.0001) and SPcmp (ρ=0.50, p=<0.0001) correlated with SPRS mobility . In the uninstructed ‘supervised free walking’ task, the correlations between spatiotemporal variability measures (Stride Time CV, Stride Length CV, Swing CV) and SPRS mobility could be confirmed; additionally, Gait Speed (ρ=-0.59, p=<0.0001) was highly correlated with SPRS mobility . Discussion We here identified trial-ready digital-motor candidate outcomes for the spastic ataxia SPG7, all characterized by proven multi-center applicability, ability to discriminate patients from controls, and correlation with measures of disease severity – even in mild disease stages –, and patient-relevant everyday function. If validated longitudinally, these sensor outcomes might inform future natural history and treatment trials in SPG7 and other spastic ataxias.
Year:
2024
Collaborators (27)
Roderick P. P. W. M. Maas
Radboud University Medical Center
Benjamin Bender
University Hospital
James Joers
University of Minnesota
Giulia Coarelli
Institut du Cerveau et de la Moelle Épinière
Henrik Zetterberg
Professor
University of Gothenburg
Ian H. Harding
Group Leader
QIMR Berghofer Medical Research Institute
Thiago Rezende
Associate Researcher
University of Campinas
Chiadi Onyike
Associate Professor
Johns Hopkins University School of Medicine
Nens van Alfen
-
Andreas Deistung
University Hospital Halle (Saale)
Kathrin Reetz
Full Professor for Translational Neurodegeneration
-
Manuela Lima
Professora Catedrática (Full Professor)
University of the Azores
Fernando Cendes
Full Professor
University of Campinas
Winfried Ilg
Senior Researcher
Hertie Institute for clinical brain research
Cynthia Gagnon
Professeure titulaire
Université de Sherbrooke
Matthis Synofzik
Professor
Hertie Institute for clinical brain research
Alexandra Durr
Professor, MD, PhD
Sorbonne Université
Amanda Heslegrave
Principal Research Fellow
University College London
David Arpin
University of Florida
Andreas Traschütz
-
Dagmar Timmann
University Hospital Essen
Jennifer Faber
Head of Ataxia Clinic
University Hospital Bonn
Janneke Grutters
Radboud University Medical Center
Marcondes França Junior
Assistant professor
University of Campinas
Jerry L. Prince
William B Kouwenhoven Professor
Johns Hopkins University
Gulin Oz
Faculty, Professor
University of Minnesota
Henry Paulson
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.